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Gene therapy by transforming growth factor-b receptor-IgG the most important biological actions of TGF-b is the
Fc chimera suppressed extracellular matrix accumulation in regulation of extracellular matrix deposition [1, 2].
experimental glomerulonephritis. TGF-b up-regulates the synthesis of individual matrixBackground. The evidence that transforming growth factor-b
components, including proteoglycans, collagens, and gly-(TGF-b) is a key mediator in the pathogenesis of fibrotic dis-
coproteins [3]. TGF-b also inhibits matrix degradationeases is now supported by several lines of investigation. This
evidence provides a certain base for targeting TGF-b as an by increasing the synthesis of protease inhibitors and
antifibrotic agent. decreasing the synthesis of proteases [4]. Finally, TGF-b
Methods. We generated a chimeric cDNA, termed TGFbRII/ alters the expression of integrins and modulates theirFc, encoding an extracellular domain of the TGF-b type II
relative proportions on the cell surface in a manner thatreceptor fused to the IgG-Fc domain, and tested whether
could facilitate adhesion to the matrix [5]. However,TGFbRII/Fc could be a novel strategy for treating glomerular
diseases. sustained or excessive expression of TGF-b, in response
Results. In cultured BNul-7 cells, recombinant TGFbRII/Fc to repeated injury, is considered to be a major rationale
reversed the antiproliferative response induced by TGF-b1. In
of glomerular matrix expansion in human and experi-addition, TGFbRII/Fc diminished the TGF-b1–induced pro-
mental glomerular disease [2, 6–8].duction of EIIIA-positive fibronectin in cultured normal rat
kidney cells. We then introduced the chimeric cDNA into the The TGF-b actions in pathophysiological conditions
muscle of the nephritic rats by the hemagglutinating virus of have now been demonstrated by several lines of evi-
Japan liposome–mediated gene transfer method in order to dence. It has been shown that the actions of TGF-bblock the TGF-b activity in nephritic glomeruli through systemic
observed in vivo can be reproduced in cultured cells bydelivery of chimeric molecules. Treatment with TGFbRII/Fc
the addition of TGF-b [2]. Intravascular injection ofgene transfection could suppress the glomerular TGF-b mRNA
in nephritic rats with a comparable effect in the reduction of TGF-b into rats or rabbits rapidly caused glomeruloscle-
extracellular matrix accumulation. rosis [9]. Overexpression of TGF-b in normal glomeruli
Conclusion. TGFbRII/Fc successfully inhibited the action by TGF-b1 gene transfection induced glomerulosclerosisof TGF-b in vitro and in vivo, and gene therapy by chimeric
within several days [10]. Hepatic expression of a TGF-b1TGFbRII/Fc might be feasible for the therapy of glomerulo-
sclerosis. transgene under the control of an albumin promoter/
enhancer in the transgenic mice resulted not only in
hepatic fibrosis, but also in renal lesions characterized by
sTransforming growth factor-b (TGF-b), a multifunc- progressive mesangial expansion and tubulointerstitial
tional cytokine, plays an important role in regulating fibrosis [11, 12]. Finally, fibrosis has been blocked in vivo
tissue repair and remodeling following injury. One of by injection of anti-TGF-b neutralizing antibodies in a
number of animal models, including kidney diseases [6].
These results support the hypothesis that modulation ofKey words: TGF-b, glomerulosclerosis, Thy-1 GN, fibrosis, injury, renal
lesions. dysregulated expression of TGF-b could preclude the
exuberant glomerular matrix deposition.Received for publication February 6, 1998
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expression by antisense oligonucleotides could suppress Here, we have examined the possibility of gene ther-
apy to determine whether TGFbRII/Fc could efficientlythe development of experimental glomerulonephritis
[13]. Furthermore, continuous delivery of decorin, which neutralize the activities of TGF-b in vitro and in vivo.
was accomplished by in vivo gene transfer into skeletal
muscle, also inhibited the extracellular matrix expansion
METHODS
in experimental glomerulonephritis [14]. Combined, this
Cell linesevidence strongly suggests the hypothesis that the inhibi-
tion of overexpressed TGF-b can ameliorate the progres- The BNul-7 mast cell line was maintained in RPMI
1640 medium supplemented with 10% fetal calf serumsion of renal diseases.
It has been shown that TGF-b signals are transduced (FCS), 5 3 1025 m of 2-mercaptoethanol, 50 U/ml of
penicillin, and 50 mg/ml of streptomycin. Normal rat kid-by simultaneously contacting two transmembrane serine/
threonine kinases known as type I and type II receptors ney (NRK) cells were propagated in Dulbecco’s modified
Eagle’s medium supplemented with 10% FCS, 50 U/ml[15]. The type II receptor recognizes the active TGF-b
ligand, whereas their type I receptor does not. Thus, of penicillin, and 50 mg/ml of streptomycin. These cell
lines were used for the growth inhibition assay and theTGF-b binds directly to the type II receptor, which is a
constitutively active kinase. The TGF-b–binding type II fibronectin induction assay for TGF-b, respectively.
receptor is then recognized by the type I receptor, which
Construction of the chimeric gene andis recruited into the complex and becomes phosphory-
purification of the chimeric moleculelated by the type II receptor. Both receptors are required
for TGF-b action in mammalian cells [16], because muta- The cDNA fragment corresponding to the extracellu-
lar domain of the human TGF-b type II receptor genetions in either receptor type disrupt signaling in each
case. Based on the differences between their ligand-bind- (codon 27 to 480) was generated by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) amplificationing properties, the type II receptor acts upstream of
the type I receptor, and thus, one may think of these from mRNA of HepG2 cells [19]. The primers used were
59-CCACTCGAGTCTGCCATGGGTCGGGGGCTGcomponents as primary receptor and transducer, respec-
tively [16]. These results motivate us to produce an inac- and 59-CCGGGATCCAAGTCAGGATTGCTGGTGT
TATATTC as sense and antisense primers, respectively.tive type II receptor construct to impede the activities
of TGF-b. However, the soluble type II receptor was For cutting out cDNA for the TGF-b type II receptor,
Xho I and BamHI restriction sites were added to sensereported to have an approximate 10-fold lower binding
affinity for TGF-b than does the cell-surface type II and antisense primers, respectively, as indicated by the
italics. The cycling parameters were 30 seconds at 948Creceptor [17]. It may partly depend on the fact that the
soluble type II receptor is monomeric, because the type and one minute at 688C. The amplification was per-
formed for 30 cycles by a GeneAmp PCR system 2400II receptor found on the cell surface is primarily a homo-
dimer and the TGF-b ligand is also a disulfide-linked (Perkin-Elmer Cetus Corp., Norwalk, CT, USA). The
fragment was cloned into the pCRII AT cloning vectordimer.
To create an efficient inhibitor with the capacity to (Invitrogen, San Diego, CA, USA). The amplified PCR
product was digested by Xho I and BamHI and insertedblock the binding of TGF-b to type II receptor and
thereby to prevent the subsequent signal transduction, into CD4Rg (a kind gift of Dr. B. Seed) from which the
Xho I BamHI fragment containing the CD4 gene waswe have generated a chimeric inhibitor molecule, termed
TGFbRII/Fc, in which the extracellular portion of the removed, thereby making a fusion gene between the N-
terminal half of TGF-bRII and the C-terminal half ofTGF-b type II receptor was fused to an immunoglobulin
heavy-chain Fc fragment. When expressed in mamma- human IgG1-Fc.
This construct was transiently transfected by using thelian cells, TGFbRII/Fc is expected to be secreted as a
disulfide-linked homodimer. The design of this molecule diethylaminoethyl (DEAE) dextran method [20] into
COS-1 cells, which were then cultured for one weekwas based on previous findings demonstrating that simi-
lar chimeric molecules possess functional binding sites with Dulbecco’s modified Eagle’s medium/F12 medium
(GIBCO Laboratories, Grand Island, NY, USA) con-and a markedly longer plasma half-life compared with
the soluble extracellular domain [18]. Repeated injection taining 1% Nutridoma-NS (Boehringer Mannheim, Mann-
heim, Germany); the chimeric molecule in the cultureof the purified recombinant TGFbRII/Fc molecule may
be applicable for molecular intervention of TGF-b ac- supernatant was purified using Prosep-A (Bioprocessing,
Princeton, NJ, USA). This purified chimeric moleculetion. However, the harvest of a large amount of purified
TGFbRII/Fc is expensive and time consuming. In con- was used for the in vitro study.
The chimeric molecule was analyzed for purity andtrast, gene transfer of TGFbRII/Fc to the skeletal muscle
is less expensive, and lasting delivery of TGFbRII/Fc dimerization by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). The purified moleculechimeric molecule could be expected.
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was resolved under nonreducing or reducing (with 0.715 Effects of the chimeric molecule on
m of 2-mercaptoethanol) conditions in 7.5% gels. After TGF-b’s fibronectin synthesis activity
transfer to nitrocellulose membranes (Hybond-c; Amer- Fibronectins comprise a family of adhesive glycopro-
sham International, Amersham, UK), the membrane was teins that are prominent components of the mesangial
blocked with phosphate-buffered saline (PBS) contain- extracellular matrix and are accumulated during glomer-
ing 5% (vol/vol) skim milk and 1% bovine serum albu- ular injury. There are several forms of fibronectins that
min, incubated with horseradish peroxidase-conjugated differ in their primary structure by the alternative splic-
avidin (Bio-Rad, Richmond, CA, USA), and developed ing of a unique mRNA precursor (pre-mRNA) tran-
using the enhanced chemiluminescence (ECL) detection scribed from a single gene; three sites of alternative splic-
reagent (Amersham Corp., Arlington Height, IL, USA). ing have so far been described—ED-A, ED-B, and
Because the extracellular domain of TGF-b type II re- IIICS—in human fibronectins and the corresponding re-
ceptor has three glycosylation sites, the reduced chimeric gions—EIIIA, EIIIB, and V—in rat fibronectins [22, 23].
molecule was also deglycosylated by N-glycosidase to Fibronectin mRNA containing EIIIA exon has been re-
address whether this chimeric molecule could be an ex- ported to increase along with the severity of the disease
pected size. After reducing the chimeric molecule, 10 mg in response to TGF-b [24].
of chimeric molecule were incubated with or without 0.4
To study the effects of the chimeric molecule on theunits of N-glycosidase F (Boehringer Mannheim) at 378C
alternative splicing of fibronectins pre-mRNA inducedovernight. Untreated chimeric molecule and chimeric
by TGF-b, we designed specific probes complementarymolecule treated with or without N-glycosidase F were
to the sequence of pre mRNA encompassing the EIIIAanalyzed through 4% to 20% SDS-PAGE. After transfer
exon for RT-PCR (Fig. 3A). The primers used were 59-to nitrocellulose membranes, the membrane was incu-
AGAACCGGAACGGAGAAAGC-39 and 59-GAGGTbated with antihuman TGF-b type II receptor antibody
GCTGTCTGGAGAAAG-39 as the sense and antisense(R&D Systems Inc., Minneapolis, MN, USA) for one hour
primers, respectively. The amplified fragments were de-and then labeled with horseradish peroxidase-conjugated
tected as 484 bp and 214 bp for EIIIA positive and EIIIAantigoat IgG (Santa Cruz, Biotechnology Inc., Santa Cruz,
negative exons, respectively.CA, USA). The membrane was washed and was then
One 3 105 NRK cells were plated in Dulbecco’s modi-developed using the ECL detection reagent (Amersham).
fied Eagle’s medium with 10% FCS in a 25 cm2 cultureFor in vivo study, pCAGGS-TGFbRII/Fc was con-
flask and were then grown to the confluency. The con-structed by inserting the Xho I-Xma III fragment con-
fluent NRK cell layer was either left untreated or in-taining a fusion gene into the Xho I site of pUC-CAGGS
cubated with 1 ng/ml of TGF-b and/or 10 mg/ml of[21], which contains the cytomegalovirus enhancer and
TGFbRII/Fc by placing them in fresh medium for twothe chicken b-actin promoter.
days. After 48 hours of exposure, the cells were washed
with PBS, and mRNA was extracted by a QuickPrepEffects of the chimeric molecule on
TGF-b’s growth inhibition activity Micro mRNA Purification kit (Quiagen, Hilden, Ger-
many). The mRNA concentrations were determined us-One 3 103 of BNul-7 cells in 96-well culture plates were
ing spectrophotometric readings at Absorbance 260. Thecultured with various concentrations of TGF-b1 (0.01
synthesis of cDNA was carried out in a 20 ml reactionng/ml to 1.25 ng/ml) in the presence or the absence of
volume containing 0.5 mg RNA from NRK cells, 0.5 mmchicken anti–TGF-b antibodies (1.25 mg/ml; R&D Sys-
dNTPs, 1 3 RT buffer (GIBCO), 0.5 mg/ml Oligo dTtems) or chimeric TGFbRII/Fc (1.25 mg/ml) for three
12–18 random primers, 10 mm dithiothreitol, and 20 Udays. Then, the BNul-7 cell growth was measured by
murine leukemia virus (MLV) reverse transcriptasethe 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrozolium
(GIBCO) incubated for one hour at 428C. One microliterbromide (MTT; Sigma Chemical Co., St. Louis, MO,
of this mixture was incubated in a 50 ml volume reactionUSA) assay. Twenty micrograms of MTT at 5 mg/ml in
with 50 pmol of primers, 0.2 mol of each dNTP, andPBS was added to each 100 ml of culture medium. After
2.5 U Taq polymerase (Perkin-Elmer Cetus Corp.) andincubation for an additional five hours at 378C, the
subjected to 25 cycles of PCR, each consisting of oneformazan crystals were dissolved by the addition of 100
minute at 948C, two minutes at 608C, and three minutesml of 10% SDS in 0.01 n HCl. The plates were then
at 728C. The amplified fragments (484 bp and 214 bp forincubated overnight, and the optical density of the wells
EIIIA positive and EIIIA negative, respectively) werewas determined using Multiskan (Labsystems, Helsinki,
analyzed by electrophoresis on agarose gels.Finland) at a wavelength of 620 nm. Within at least one
hour, the plates were read on a micro-enzyme-linked
Preparation of hemagglutinating virus ofimmunosorbent assay reader at a wavelength of 570 nm
Japan liposomeand a reference wavelength of 620 nm. The results of
The chimeric TGFbRII/Fc gene was transfected to thethe inhibition studies are presented as a percentage of
TGF-b–free proliferation of BNul-7 cells. gluteal muscle of nephritic rats by the of hemagglutinat-
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ing virus of Japan (HVJ) liposome gene transfer method Detection of chimeric gene expression
[10, 13, 14], which has been employed for transient trans- Total RNA was isolated from the skeletal muscle of
fection in vivo. The HVJ liposomes were prepared as TGFbRII/Fc gene-transferred nephritic rat, and the iso-
described previously [10, 13, 14]. Briefly, phosphatidyl- lated RNA was subsequently reversed transcribed into
serine, phosphatidylcholine, and cholesterol were mixed cDNA. To examine the expression of chimeric gene, sense
in a weight ratio of 1:4.8:2. Dried lipid was hydrated in and antisense primers were designed from the cDNA se-
200 ml of balanced salt solution (BSS) containing 200 quences of the extracellular domain of the TGF-b type
mg of pCAGGS-TGFbIIR/Fc, vortexed vigorously, and II receptor and IgG-Fc hinge region, respectively. The
primers used were 59-TCCTGTGGACGCGTATCGC-39sonicated to form liposomes. The liposomes were incu-
and 59-GAGTTTTGTCACAAGATTTGGG-39 as thebated with purified HVJ inactivated by ultraviolet irradi-
sense and antisense primers, respectively. The amplifiedation (110 erg/mm2/sec) for three minutes just before
fragment was detected as 420 bp for spliced TGFbRII/use. The liposome suspensions (containing 10 mg of lipids)
Fc mRNA.were mixed with HVJ (30,000 hemagglutinating units) in
Three days after transfection, untreated nephritic ratsa total volume of 2 ml BSS. The mixture was incubated
and TGFbRII/Fc gene-transfected rats were sacrificed,at 48C for 10 minutes and was gently shaken for 60 minutes
and then the kidneys were removed and were fixed inat 378C. Free HVJ was removed from the HVJ liposomes
methylcarn solution. Glomerular deposition of TGFbRII/by discontinuous density gradient centrifugation with su-
Fc molecule was stained with the monoclonal antibodycrose. The HVJ-liposome suspension contained approxi-
to human IgG-Fc (Caltag Laboratories, San Francisco,mately 20 mg of pCAGGS-TGFbRII/Fc in 1 ml BSS and
CA, USA).was maintained at 48C.
Glomerular RNA preparation andIn vivo experimental design
Northern blot analysis
On day 0, to induce anti-Thy-1 model of experimental To examine the effects on the level of TGF-b1 and
glomerulonephritis, the anti-Thy-1 antibody OX-7 (1.0 type I collagen mRNA, Northern blot analysis was per-
mg/kg; a gift from Dr. Kenichi Isobe and Dr. Seiichi formed with glomerular RNA extracted from nephritic
Matsuo, Nagoya University, Japan) was administrated rats treated with 0 mg, 5 mg, or 20 mg of pCAGGS-
intravenously to six-week-old male Sprague-Dawley rats TGFbRII/Fc chimeric gene transfection. Six days after
(Japan SLC, Inc., Hamamatsu, Japan). On day 1, ne- transfection (seven days after disease induction), total
phritic rats were anesthetized by ether, and the left glu- RNA was prepared from pooled glomeruli that were
teal muscles were exposed. HVJ-liposome solutions en- isolated from the minced kidneys of six rats together in
capsulating 0 mg, 5 mg, or 20 mg of pCAGGS-TGFbRII/ each group by the graded sieving technique as described
Fc were then injected into the gluteal muscles of the previously [13, 14]. For the Northern blot analysis, 20
nephritic rats. Three days after transfection, three un- mg aliquots of total RNA were separated on 1% agarose
formaldehyde gel and were transferred onto nylon mem-treated nephritic rats and three TGFbRII/Fc gene-trans-
branes (Hybonde-N; Amersham). TGF-b1, type I colla-ferred nephritic rats were sacrificed, and kidney and skel-
gen, and GAPDH cDNA [13, 25] were labeled by theetal muscle were removed to examine the expression of
random priming method using [a-32P] dATP (3000 Ci/chimeric gene. On day 7, the kidneys from six untreated
mmol; Amersham). Hybridization was carried out at 428Cnephritic rats and six of the 5 mg or 20 mg of pCAGGS-
overnight in 50% formamide, 10 3 Denhardt’s solution,TGFbRII/Fc gene-transfected nephritic rats were per-
1% SDS, 5 3 SSC, 50 mm Na phosphate, and 200 mg/mlfused with cold autoclaved PBS, and samples of the cor-
salmon sperm DNA. The blots were washed three timestex were taken for histology. Tissues for light microscopy
at 508C in 0.5 3 SSC and 0.1% SDS, and the signalswere fixed with 4% paraformaldehyde overnight and
were quantitated by laser densitometry (ScanningImager;dehydrated through a graded ethanol series and embed-
Molecular Dynamics, Sunnyvale, CA, USA).ded in paraffin. Histologic sections (2 mm) of kidneys
were stained with periodic acid-Schiff reagent. To quan- Statistical analysis
titate mesangial matrix accumulation, all sections were All values are expressed as mean 6 se. Statistical
evaluated by an observer unaware of the experimental significance (defined as P , 0.01) was evaluated using
protocol. Thirty glomeruli were selected at random in the one-way analysis of variance.
cross-sections from each rat. The degree of mesangial
matrix accumulation was determined as the percentage
RESULTSof each glomerulus occupied by the mesangial matrix
Purification of TGFbRII/Fcas described previously [13, 14]. For glomerular RNA
preparations, glomeruli were isolated from the re- TGFbRII/Fc was created by cDNA encoding the ex-
tracellular domain of the human TGF-b type II receptormaining tissue by a standard sieving method.
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Fig. 2. Western blot analysis of the chimeric TGFbRII/Fc molecule
deglycosylated by N-glycosidase F. Molecular weight standards are kilo-
daltons (lane 1). Untreated reduced chimeric TGFbRII/Fc molecule
(lane 2), chimeric TGFbRII/Fc molecule incubated without (lane 3),
or with N-Glycosidase F (lane 4) was analyzed by Western blot analysis
incubated with antihuman TGF-b type II receptor antibody.
Fig. 1. SDS-PAGE analysis of the chimeric TGFbRII/Fc molecule
purified by protein A sepharose chromatography. The proteins were to be an associated dimer with an apparent molecularvisualized by Coomassie brilliant Blue staining. Molecular weight stan-
weight of approximately 130 kDa. Upon reduction (withdards are kilodaltons (lane 1). The purified chimeric TGFbRII/Fc mole-
cule was subjected under nonreducing (lane 2; 2-ME2) or reducing 0.715 m of 2-mercaptoethanol), it runs at approximately
(lane 3; 2-ME1) conditions. 65 kDa. Both samples migrate considerably higher on
the gels than their predicted molecular weight (45 kDa).
However, deglycosylating the chimeric molecule using
N-glycosidase altered the molecular weight to 45 kDa,ligated to the cDNA for the Fc portion of the human
IgG1 heavy chain. The immunoglobulin portion of this suggesting that this chimeric molecule was secreted after
glycosylation (Fig. 2).fusion molecule contains the hinge and constant region
CH2 and CH3 domains. These fusion molecules lack
Effects of the chimeric molecule onthe TGF-b type II receptor transmembrane domain but
TGF-b’s growth-inhibition activitycontain the IgG heavy-chain hinge region Cys residues
and, therefore, should be secreted from cells as a soluble To characterize the in vitro properties of the chimeric
molecule consisting of the TGF-b type II receptor fuseddimer.
Based on the primary structure of the extracellular to the IgG-Fc domain, the recombinant chimeric mole-
cule was purified. Because the TGFbRII/Fc chimericdomain connected with the IgG-Fc molecule, our model
predicts that these molecules will behave as homodimers, molecule was expected to act as a competitive antagonist
for TGF-b, we assessed whether the recombinant chime-by virtue of the IgG hinge region. Analysis of the purified
molecules by SDS-PAGE under both reducing (with ric TGFbRII/Fc molecule could attenuate the effects
of TGF-b on the growth-inhibiting action. To test this0.715 m of 2-mercaptoethanol) and nonreducing condi-
tions demonstrates the purity of the preparations and possibility, BNul-7 cells, which express the native TGF-b
receptors, were treated with TGF-b1, and cell growthconfirms the predicted homodimer structure of the na-
tive chimeric molecules (Fig. 1). Under nonreducing con- was measured by an MTT assay in the presence of either
TGFbRII/Fc (1.25 mg/ml) or anti–TGF-b antibodiesditions, the TGFbRII/Fc chimeric molecule is estimated
Isaka et al: Gene therapy by TGF-bR chimera470
Detection of chimeric gene expression
To show the feasibility of the chimeric gene transfer
into muscle, we examined the TGFbRII/Fc gene expres-
sion in the transfected muscle by using the specific prim-
ers encompassing the extracellular domain of the TGF-b
type II receptor and IgG-Fc hinge region (Fig. 5A). Am-
plification with the specific primer set revealed the pres-
ence of transcript for the 420 bp product in the cDNA
obtained from TGFbRII/Fc-transfected muscle (lane 1).
However, an extract from TGFbRII/Fc transfected mus-
cle (without reverse transcription; lane 2) did not result
in a 420 bp product.
Fig. 3. Effects of the chimeric molecule on TGF-b’s growth inhibition Immunohistochemical staining with the monoclonalactivity. One 3 103 of BNul-7 cells were cultured with TGF-b (0.01 ng/
antibody to human IgG-Fc unveiled the glomerular de-ml to 1.25 ng/ml) in the absence (m) or presence of chicken anti-TGF-b
antibodies (j) or chimeric TGFbRII/Fc (d) for three days. Three days position of chimeric TGFbRII/Fc molecule in the mesan-
later, the growth of the BNul-7 cells was measured by MTT assay. At gial area three days after transfection (Fig. 5B), whereasconcentrations from 0.01 ng/ml to 1.25 ng/ml of TGF-b, the growth of
there was no deposition in the glomeruli of untreatedBNul-7 cells was inhibited by TGF-b1 in a dose-dependent manner.
Both anti-TGF-b antibodies and chimeric TGFbRII/Fc completely disease control rats (Fig. 5C).
blocked the growth inhibitory action of TGF-b1.
Inhibition of TGF-b1 expression in
nephritic glomeruli
(1.25 mg/ml). At concentrations from 0.01 ng/ml to 1.25 Given the competitive properties of chimeric TGFbRII/
ng/ml of TGF-b, the growth of BNul-7 cells was inhibited Fc against TGF-b1 in vitro, we assessed the feasibility
by TGF-b1 in a dose-dependent manner. Both anti– of chimeric gene transfer in vivo. HVJ-liposome solution
TGF-b antibodies (1.25 mg/ml) and chimeric TGFbRII/ containing 5 mg or 20 mg of pCAGGS-TGFbRII/Fc was
Fc (1.25 mg/ml) completely blocked the growth inhibitory introduced into the gluteal muscles of nephritic rats one
action of TGF-b1 (Fig. 3). day after injection of the OX-7 antibody. HVJ-liposome
solution without DNA was also examined in nephriticEffects of the chimeric molecule on
rats as untreated disease controls. On day 7, we obtainedTGF-b’s matrix-synthesis activity
glomerular RNA to examine whether the chimeric
For an alternative approach to identifying the proper- TGFbRII/Fc gene transfection could reduce the message
ties of TGFbRII/Fc as a competitive antagonist for of TGF-b1 and type I collagen in glomeruli. Glomeruli
TGF-b1, we addressed whether recombinant chimeric were isolated by the graded sieving technique, and
TGFbRII/Fc molecule could manipulate the effects of Northern blot analysis was performed to compare the
TGF-b on the extracellular matrix synthesis. NRK cells
levels of TGF-b1 and type I collagen mRNA. The
were treated with TGF-b1 (1 ng/ml), and the expression
TGF-b1 and type I collagen mRNA levels were elevatedof fibronectin EIIIA was measured in the presence or
by more than 10- and 12-fold in untreated disease con-absence of TGFbRII/Fc (10 mg/ml). Alternative splicing
trols seven days after OX-7 injection, respectively. Laserat EIIIA exon generates two types of fibronectin mRNA
densitometric analysis revealed that TGF-b1 mRNA ex-that differ in terms of the presence or absence of the
pression in glomeruli from nephritic rats transfected withEIIIA sequences. The two fibronectin mRNA variants
5 mg and 20 mg of the chimeric gene was reduced to 48%EIIIA1 (with EIIIA exon) and EIIIA2 (without EIIIA
and 39% of that in untreated disease controls, respec-exon) were examined by the RT-PCR method. EIIIA1
tively (Fig. 6). The effect of TGFbRII/Fc transfectionfibronectin is considered to be a specific marker for
on type I collagen mRNA expression was observed asTGF-b activity and matrix accumulation, because it is
a similar pattern. The level of GAPDH mRNA remainedalmost undetectable in normal adult rat glomeruli and
unaffected in all transfected kidneys.is strongly induced by TGF-b [24].
Exposed to TGF-b1, EIIIA1 fibronectin mRNA in-
Suppression of extracellular matrix expansion increased over control NRK cells, whereas EIIIA2 fibro-
nephritic glomerulinectin mRNA increased slightly. There was a clear re-
Given the effective suppression of TGF-b1 messageduction in EIIIA1 after treatment with the purified
production, we assessed the inhibitory action of chimericchimeric molecule even though the reduction of EIIIA2
gene transfection on the histologic changes in the kidneywas much less dramatic (Fig. 4). Thus, the chimeric
on day 7. Figure 7 shows the representative appearanceTGFbRII/Fc molecule also inhibits the TGF-b–induced
extracellular matrix synthesis. of the glomeruli. In the kidneys from the untreated ne-
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Fig. 4. Effects of the chimeric TGFbRII/Fc
on TGF-b’s fibronectin synthesis activity. (A)
Specific probes complementary to mRNA, en-
compassing EIIIA exon for RT-PCR. The am-
plified fragments were detected as 484 and 214
bp for EIIIA1 and EIIIA2, respectively. (B)
The effects of chimeric TGFbRII/Fc on EIIIA
expression. NRK cells were incubated with
medium alone (lane 1) or 1 ng/ml of TGF-b1
(lane 2). TGF-b1–treated NRK cells were
coincubated with 10 mg of TGFbRII/Fc chi-
meric protein (lane 3). The expression of fi-
bronectin EIIIA was measured by RT-PCR
by using specific primers.
phritic rats, the glomeruli exhibited marked increases in the pathogenesis of human and experimental glomerular
mesangial extracellular matrix. In contrast, chimeric disease [1, 2, 7, 8, 11, 12]. In conditions characterized by
gene transfection markedly suppressed the increase in chronic inflammation and fibrosis caused by overpro-
mesangial matrix expansion. Semiquantitative analysis duced TGF-b, blocking the action of TGF-b seems very
of mesangial matrix indices is summarized in Figure 8. promising. Therefore, there is considerable interest in
The mesangial matrix indices of glomeruli from the kid- potential therapeutic applications to manipulate TGF-b
neys untransfected, 5 mg transfected, and 20 mg trans- actions in glomerular disease by gene therapy. It seems
fected were 3.1 6 0.4, 2.1 6 0.5, and 1.9 6 0.6, respec- that there are two clear possible therapeutic strategies
tively. These results demonstrated that chimeric TGFbRII/ for decreasing the action of TGF-b that may be more
Fc gene transfer one day after disease induction could suitable than antibodies in humans. We have been ac-
suppress extracellular matrix expansion. tively investigating the potential of molecular biological
intervention to antagonize the action of TGF-b in glo-
merular diseases in two ways: One strategy is a directDISCUSSION
inhibition of TGF-b synthesis by application of antisenseTransforming growth factor-b is a key cytokine in
oligodeoxynucleotides [13], and the other is gene transferwhich its actions in promoting the production and depo-
of an inhibitory molecule against TGF-b, such as decorin,sition of extracellular matrices are essential for normal
a small proteoglycan, by competitively blocking the ac-tissue repair following injury, and sustained or excessive
expression of TGF-b is considered to be clearly causal in tive TGF-b binding to the cognate receptor [14].
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Fig. 6. Northern blot analysis of the chimeric TGFbRII/Fc gene trans-
fection on glomerular TGF-b1 and type I collagen mRNA in nephritic
rats. The glomeruli were obtained from age-matched normal control
rats (lane 1), untreated disease control kidneys (lane 2), and the kidneys
from nephritic rats treated with 5 mg of DNA (lane 3) and 20 mg of
DNA (lane 4) transfection.
In this study, we generated a fusion protein in which
TGF-b type II receptor cDNA encoding extracellular
domain was recombined in frame with the Fc portion of
the human immunoglobulin IgG1 heavy-chain cDNA at
the hinge region. Because of the T-cell receptor and
CD4 immunoadherin fusion proteins [18], receptor-IgG
chimeras have been used for structural and functional
studies of the Ig-like superfamily of receptors, including
c-kit [26] and the platelet-derived growth factor receptor
[27]. The ligand-binding properties of other non-Ig-like
receptors, including the natriuretic peptide receptors
[28], tumor necrosis factor receptor [29], and hepatocyte
growth factor receptor [30], have been analyzed by
means of secreted immunoglobulin fusion proteins as
well. It was reported that dimeric tumor necrosis factor
receptor-IgG heavy-chain chimeric protein was quite ef-
fective as a tumor necrosis factor inhibitor. In contrast,
the monovalent extracellular portion had a greatly re-
duced tumor necrosis factor inhibitory activity compared
with that of the bivalent inhibitor [29]. Therefore, we
Fig. 5. Detection of chimeric gene expression. (A) RT-PCR for chime-
ligated the variable and CH1 domains from the heavyric TGFbRII/Fc mRNA expression. Total RNA was isolated from the
skeletal muscle of TGFbRII/Fc gene-transferred nephritic rat, and the chain with the extracellular domain of the TGF-b type II
isolated RNA was subsequently reversed transcribed into cDNA. cDNA receptor to the random structure of the hinge to facilitate
obtained from TGFbRII/Fc transfected muscle (lane 1) was amplified
dimer secretion and to allow maximal adaptability to theby using the specific primers encompassing the extracellular domain of
the TGF-b type II receptor and the IgG-Fc hinge region. The amplified
fragment was detected as 420 bp for spliced TGFbRII/Fc mRNA. Ex-
tracted product obtained from TGFbRII/Fc transfected muscle was also
amplified without reverse transcription (lane 2). (B) Immunohistochem-
ical staining of a glomerulus from nephritic rat with the monoclonal
monoclonal antibody to human IgG-Fc, demonstrating that there wasantibody to human IgG-Fc three days after TGFbRII/Fc gene transfec-
no deposition in disease control kidney.tion. (C) Untreated disease control kidney was also stained with the
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Fig. 8. Semiquantitation of the pathological effects of chimeric
TGFbRII/Fc gene transfection. The severity of the glomerular damage
of the untreated disease control kidneys and the kidneys from nephritic
rats treated with 5 mg of DNA and 20 mg of DNA transfection was
evaluated by extracellular matrix accumulation. The values are ex-
pressed as mean 6 se. *P , 0.001 vs. the other groups. Each group
contained six animals.
in BNul-7 cells (Fig. 3), and (b) recombinant chimeric
TGFbRII/Fc protein (10 mg/ml) diminished EIIIA1
mRNA induced by TGF-b (1 ng/ml) below the control
level of untreated NRK cells (Fig. 4).
The chimeric-soluble TGF-b receptor is a secreted
protein, and when the expression vector is transferred
in the skeletal muscle, soluble TGF-b receptors would
be expected to increase the secretion and delivery to the
kidneys via the bloodstream in the context of a disulfide-
linked dimer. RT-PCR analysis of the chimeric gene-trans-
fected muscle demonstrated that processed TGFbRII/Fc
mRNA was expressed three days after transfection (Fig.Fig. 7. Effects of chimeric TGFbRII/Fc gene transfection on the pro-
gression of anti-Thy-1 glomerulonephritis on day 7. Micrographs show 5A). When transfected into muscle, gene expression was
representative results of periodic acid-Schiff staining of glomeruli from observed until at least 14 days [14]. The chimeric soluble
untreated disease control kidneys (A), 5 mg of DNA transfected (B),
receptor with IgG-Fc was also reported to confer advan-and 20 mg of DNA transfected (C) nephritic rats (3400).
tage for in vivo studies because of its extended plasma
half-life [18]. It would thus appear that adding an IgG
heavy chain as a partner in chimeric molecules may be
ligand of TGF-b. In fact, SDS-PAGE analysis demon- a useful strategy for the expression of molecules that
strated that TGFbRII/Fc is processed to a two-chain would otherwise prove unstable in circulation.
form when expressed in COS cells such as the cell-associ- The phenomenon of protein deposition in the glomer-
ated TGF-b type II receptor (Fig. 1). Our data confirmed ulus is well known and has been extensively studied.
that indeed, recombinant chimeric TGFbRII/Fc was a Deposition of the molecule in the glomerulus depends
competitive antagonist of TGF-b in two ways: (a) Re- on the size and charge of the molecule, and the capability
combinant chimeric TGFbRII/Fc (1.25 mg/ml) com- of the molecule phagocytosed/endocytosed by mesangial
cells. Anionic antigens or antigens with a large size havepletely blocked the growth inhibitory action of TGF-b
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a tendency to form deposits in the mesangium. Large contents, but identical tensile strength and more normal
dermal architecture than the other wounds. We haveparticles may enter the mesangium through fenestrated
endothelium. It remains unclear why the large size and seen no such adverse effects in our work with chimeric
gene transfer. Extreme reduction of TGF-b levels mayanionic property of the molecule determine its mesangial
localized deposition; however, it may be feasible that a be pathological; however, our results show that chimeric
gene transfer suppressed TGF-b1 mRNA expression,portion of the molecule enables the specific delivery to
the mesangium. Employing this concept (delivering a spe- but the level of TGF-b1 was over the normal level, and
it is unlikely that gene transfer renders cells unresponsivecific molecule into the glomerulus via gene transfer to a
nonrenal organ) we have already shown that the decorin to normal signal transduction of TGF-b1. For these rea-
sons, we feel that suppressing TGF-b with chimeric genesecreted from the transfected muscle could target the
glomerulus and block the fibrotic actions of TGF-b [14]. therapy will be safe. However, the long-term conse-
quences of reducing TGF-b levels are unknown, and theHere, it was also shown that the chimeric TGFbRII/Fc
molecule was detected in the mesangial area (Fig. 5B), possibility of adverse effects must be carefully studied.
indicating that TGFbRII/Fc was produced in the muscle In conclusion, we constructed a chimeric molecule de-
and delivered to the kidney. signed specifically to inhibit TGF-b–mediated glomerular
Of interest is that chimeric TGFbRII/Fc treatment matrix accumulation. The TGFbRII/Fc binds TGF-b1,
reduced the increase in TGF-b1 mRNA levels. This find- thereby blocking the biological activities of TGF-b in
ing strongly supports the hypothesis that a positive feed- vitro. Moreover, the transfection of the TGFbRII/Fc
back system exists for stimulation of TGF-b production gene into the muscles of nephritic rats prevented glomer-
by TGF-b, by itself, in glomeruli [31] and that the binding ular matrix expansion in vivo. These results suggest that
of TGF-b to a chimeric TGFbRII/Fc intercepted the TGFbRII/Fc may prove to be clinically useful, given
positive feedback pathway. These results suggest that the that blocking of TGF-b overexpression in the glomeruli
characteristic features of glomerular lesions are largely provides a potentially powerful therapeutic approach to
mediated by increased endogenous TGF-b activity in the treatment of TGF-b–mediated glomerular diseases.
the kidney and that these manifestations can also be
attenuated by blocking TGF-b. ACKNOWLEDGMENTS
The HVJ liposome-mediated transfer of a TGF-b in-
This work was supported by grants from Grant in Aid for Scientific
hibitor gene in the muscle represents a means for impos- Research (B), Grant in Aid of Minister of Health and Welfare, the
Japan Health Sciences Foundation, Takeda Medical Research Founda-ing the blockade of TGF-b activity in nephritic glomeruli
tion, and the Baxter’s Extramural Grant Program.and maintaining it for a few weeks. Conceptually, the
approach that we used differs from the infusion of recom- Reprint requests to Dr. Enyu Imai, First Department of Medicine,
Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osakabinant inhibitory proteins, in that the function of the
565–0871, Japan.overexpressed TGF-b has been abrogated by the intro-
E-mail: kidney@medone.med.osaka-u.ac.jp
duction of an artificial gene, the product of which neutral-
izes TGF-b. Gene therapy has several important advan-
REFERENCEStages over therapy with a recombinant protein. For
1. Border WA, Ruoslahti E: Transforming growth factor-beta inexample, it does not require repeated intravascular injec-
disease: The dark side of tissue repair. J Clin Invest 90:1–7, 1992tions for administration; this may significantly improve 2. Border WA, Noble NA: Transforming growth factor beta in tissue
compliance. Sustained production and secretion of the fibrosis. N Engl J Med 331:1286–1292, 1994
3. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevatedprotein by muscle cells may lead to continuously retained
expression of transforming growth factor-beta and proteoglycanconcentrations and a greater therapeutic effect than if production in experimental glomerulonephritis: Possible role in
administered by intravascular injection. Finally, and im- expansion of the mesangial extracellular matrix. J Clin Invest
86:453–462, 1990portantly, gene therapy is advantageous because it is less
4. Tomooka S, Border WA, Marshall BC, Noble NA: Glomerularexpensive and overcomes the need to manufacture and matrix accumulation is linked to inhibition of the plasmin protease
purify a recombinant protein. system. Kidney Int 42:1462–1469, 1992
5. Kagami S, Border WA, Ruoslahti E, Noble NA: CoordinatedBlocking TGF-b with antibodies is therapeutic in a
expression of beta 1 integrins and transforming growth factor-number of models of fibrotic disease in other organs.
beta-induced matrix proteins in glomerulonephritis. Lab Invest
None of the studies reported any adverse effects of treat- 69:68–76, 1993
6. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchiing animals by neutralizing TGF-b antibodies [2]. It was
YU, Pierschbacher MD, Ruoslahti E: Natural inhibitor of trans-reported that the injection of neutralizing antibody for
forming growth factor-beta protects against scarring in experimen-
TGF-b into dermal wounds healed without scar tissue tal kidney disease. Nature 360:361–364, 1992
7. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Borderformation, whereas all control wounds with irrelevant
WA: Expression of transforming growth factor beta is elevated inantibodies or TGF-b injection healed with scarring [32].
human and experimental diabetic nephropathy. Proc Natl Acad
Neutralizing antibody-treated wounds had fewer macro- Sci USA 90:1814–1818, 1993
8. Yamamoto T, Noble NA, Miller DE, Border WA: Sustainedphages and blood vessels, lower collagen and fibronectin
Isaka et al: Gene therapy by TGF-bR chimera 475
expression of TGF-beta 1 underlies development of progressive antigen) cDNAs by a COS cell expression system. EMBO J 6:3313–
3316, 1987kidney fibrosis. Kidney Int 45:916–927, 1994
9. Terrell TG, Working PK, Chow CP, Green JD: Pathology of 21. Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-
expression transfectants with a novel eukaryotic vector. Generecombinant human transforming growth factor-beta 1 in rats and
rabbits. Int Rev Exp Pathol 34(Part B):43–67, 1993 108:193–199, 1991
22. Pagani F, Zagato L, Vergani C, Casari G, Sidoli A, Baralle10. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E:
Glomerulosclerosis induced by in vivo transfection of transforming FE: Tissue-specific splicing pattern of fibronectin messenger RNA
precursor during development and aging in rat. J Cell Biolgrowth factor-beta or platelet-derived growth factor gene into the
rat kidney. J Clin Invest 92:2597–2601, 1993 113:1223–1229, 1991
23. Schwarzbauer JE, Patel RS, Fonda D, Hynes RO: Multiple sites11. Kopp JP, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger
EP, Klothman PE, Thorgeirsson SS: Transgenic mice with in- of alternative splicing of the rat fibronectin gene transcript. EMBO
J 6:2573–2580, 1987creased plasma levels of TGF-beta1 develop progressive renal dis-
ease. Lab Invest 74:991–1003, 1996 24. Alonso J, Gomez-Chiarri M, Ortiz A, Seron D, Condom E,
Lopez-Armada MJ, Largo R, Barat A, Egido J: Glomerular up-12. Sanderson N, Factor V, Nagy P, Kopp P, Kondaiah P, Wakefield
L, Roberts AB, Sporn MB, Thorgeirsson SS: Hepatic expression regulation of EIIIA and V120 fibronectin isoforms in proliferative
immune complex nephritis. Kidney Int 50:908–919, 1996of mature transforming growth factor beta 1 in transgenic mice
results in multiple tissue lesions. Proc Natl Acad Sci USA 92:2572– 25. Kaneko T, Moriyama T, Imai E, Akagi Y, Arai M, Inoue T, Xia
C, Noguchi T, Kamada T, Ueda N: Expression of transmembrane-2576, 1995
13. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama type protein tyrosine phosphatase mRNA along rat nephron seg-
ments. Am J Physiol 268:F1102–F1108, 1995T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E:
Inhibition of TGF-beta 1 expression by antisense oligonucleotides 26. Liu YC, Kawagishi M, Kameda R, Ohashi H: Characterization
of a fusion protein composed of the extracellular domain of c-kitsuppressed extracellular matrix accumulation in experimental glo-
merulonephritis. Kidney Int 50:148–155, 1996 and the Fc region of human IgG expressed in a baculovirus system.
Biochem Biophys Res Commun 197:1094–1102, 199314. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA,
Border WA: Gene therapy by skeletal muscle expression of de- 27. Heidaran MA, Mahadevan D, Larochelle WJ: Beta PDGFR-
IgG chimera demonstrates that human beta PDGFR Ig-like do-corin prevents fibrotic disease in rat kidney. Nature Med 2:418–423,
1996 mains 1–3 are sufficient for high affinity PDGF BB binding. FASEB
J 9:140–145, 199515. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mech-
anism of activation of the TGF-beta receptor. Nature 370:341–347, 28. Bennett BD, Bennett GL, Vitangcol RV, Jewett JRS, Burnier
J, Henzel W, Lowe DG: Extracellular domain-IgG fusion proteins1994
16. Massague J: TGFb signaling: Receptors, transducers, and mad for three human natriuretic peptide receptors. J Biol Chem
266:23060–23067, 1991proteins. Cell 85:947–950, 1996
17. Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish 29. Peppel K, Crawford D, Beutler B: A tumor necrosis factor (TNF)
receptor-IgG heavy chain chimeric protein as a bivalent antagonistHF: The soluble exoplasmic domain of the type II transforming
growth factor (TGF)-beta receptor: A heterogeneously glycosy- of TNF activity. J Exp Med 174:1483–1489, 1991
30. Mark MR, Lokker NA, Zioncheck TF, Luis EA, Godowski PJ:lated protein with high affinity and selectivity for TGF-beta ligands.
J Biol Chem 270:2747–2754, 1995 Expression and characterization of hepatocyte growth factor recep-
tor-IgG fusion proteins. J Biol Chem 267:26166–26171, 199218. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T,
Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder 31. Sharma K, Jin Y, Guo J, Ziadeh FN: Neutralization of TGF-b
by anti-TGF-b antibody attenuates kidney hypertrophy and theS, Smith DH: Designing CD4 immunoadhesins for AIDS therapy.
Nature 337:525–531, 1989 enhanced extracellular matrix gene expression in STZ-induced
diabetic mice. Diabetes 45:522–530, 199619. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF:
Expression cloning of the TGF-beta type II receptor: A functional 32. Shah M, Foreman DM, Ferguson MW: Control of scarring in
adult wounds by neutralising antibody to transforming growthtransmembrane serine/threonine kinase. Cell 68:775–785, 1992
20. Aruffo A, Seed B: Molecular cloning of two CD7 (T-cell leukemia factor beta. Lancet 339:213–214, 1992
